Baloxavir: meta-analysis of COVID-19 studies

All studies Ventilation ICU Serious outcomes Recovery Viral clearance RCTs Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−200%

Ventilation (1)−200%

ICU admission (1)−200%

Viral clearance (1)−600%

RCTs (1)−200%

Late (1)−200%

00.511.5+

← Baloxavir
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Baloxavir COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Lou (RCT)−200%3.00 · 0.14–65.91ventilation1/100/10

Late treatment−200%3.00 · 0.14–65.911/100/10200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−200%3.00 · 0.14–65.911/100/10200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Baloxavir
reduces riskBaloxavir
increases risk →

c19early.org

October 2026

Baloxavir COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Lou (RCT)−200%3.00 · 0.14–65.911/100/10

Late treatment−200%3.00 · 0.14–65.911/100/10200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−200%3.00 · 0.14–65.911/100/10200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Baloxavir
reduces riskBaloxavir
increases risk →

c19early.org

October 2026

Baloxavir COVID-19 ICU results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Lou (RCT)−200%3.00 · 0.14–65.911/100/10

Late treatment−200%3.00 · 0.14–65.911/100/10200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−200%3.00 · 0.14–65.911/100/10200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Baloxavir
reduces riskBaloxavir
increases risk →

c19early.org

October 2026

Baloxavir COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Lou (RCT)−200%3.00 · 0.14–65.91ventilation1/100/10

Late treatment−200%3.00 · 0.14–65.911/100/10200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−200%3.00 · 0.14–65.911/100/10200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Baloxavir
reduces riskBaloxavir
increases risk →

c19early.org

October 2026

Baloxavir COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Lou (RCT)20%0.80 · 0.30–2.13no recov.4/105/10

Late treatment20%0.80 · 0.30–2.134/105/1020% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.67

All studies20%0.80 · 0.30–2.134/105/1020% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.6700.511.52+

Rotate screen for more detailsIncrease width for more details

← Baloxavir
reduces riskBaloxavir
increases risk →

c19early.org

October 2026

Baloxavir COVID-19 viral clearance results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Lou (RCT)−600%7.00 · 0.41–120viral+3/100/10

Late treatment−600%7.00 · 0.41–1203/100/10600% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.18

All studies−600%7.00 · 0.41–1203/100/10600% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1800.511.52+

Rotate screen for more detailsIncrease width for more details

← Baloxavir
reduces riskBaloxavir
increases risk →

c19early.org

October 2026

Baloxavir COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Lou (RCT)−200%3.00 · 0.14–65.91ventilation1/100/10

Late treatment−200%3.00 · 0.14–65.911/100/10200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−200%3.00 · 0.14–65.911/100/10200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Baloxavir
reduces riskBaloxavir
increases risk →

c19early.org

October 2026

Baloxavir COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Lou (RCT)−200%3.00 · 0.14–65.91ventilation1/100/10

Late treatment−200%3.00 · 0.14–65.911/100/10200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−200%3.00 · 0.14–65.911/100/10200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Baloxavir
reduces riskBaloxavir
increases risk →

c19early.org

October 2026

Baloxavir COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Lou (RCT)−200%3.00 · 0.14–65.91ventilation1/100/10 Lou (RCT)−200%3.00 · 0.14–65.91ICU1/100/10 Lou (RCT)20%0.80 · 0.30–2.13no recov.4/105/10 Lou (RCT)0%1.00 · 0.75–1.34no recov.9/109/10 Lou (RCT)−600%7.00 · 0.41–120viral+3/100/10 Lou (RCT)20%0.80 · 0.30–2.13viral+4/105/10

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Baloxavir
reduces riskBaloxavir
increases risk →